30年心脏移植:单中心机械循环支持后结局
该研究回顾性分析1988至2019年单中心463例原发移植、224例CF-LVAD、49例搏动性LVAD及71例临时MCS的心脏移植患者。按MCS状态分层生存无显著差异(P=.18);现代队列中CF-LVAD与临时MCS生存不劣于原发移植(P=.22),术后主要并发症无差异。
要点
- 按移植前MCS状态分层,各组生存无显著差异(P=.18)
- 现代队列CF-LVAD及临时MCS生存不劣于原发移植(P=.22)
- CF-LVAD已成为该中心近十年多数移植来源,未增加并发症
核心结论
- CF-LVAD已成为该中心近十年多数心脏移植的来源,对生存及术后并发症无不良影响。
- 临时MCS在2018年移植名单标准变更后使用增加,早期结局可接受。
研究设计与样本
- 单中心回顾性研究,1988至2019年原位心脏移植病例。
- 按移植前MCS状态分为CF-LVAD(n=224)、搏动性LVAD(n=49)、临时MCS(n=71)及原发移植(n=463)组。
- 对CF-LVAD获批用于桥接移植后至2018年分配政策变更前的患者行亚组分析,评估现代队列生存预测因素与并发症。
主要发现
- 研究期间原发移植比例由88%降至14%。
- 按MCS状态分层未检出生存显著差异(P=.18)。
- 现代队列中CF-LVAD与临时MCS患者生存不劣于原发移植(P=.22)。
- 长期死亡预测因素包括较低体重指数、外周血管病、既往冠状动脉旁路移植、ABO非一致移植及供者年龄增加(均P≤.02)。
- 主要术后并发症无差异。
临床怎么用
- 支持CF-LVAD作为桥接移植的常规选择,未增加术后主要并发症。
- 2018年名单标准变更后临时MCS使用增加,早期结局可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival after bridge to transplantation with mechanical circulatory support (MCS) has yielded varying outcomes on the basis of device type and baseline characteristics. Continuous-flow left ventricular assist devices (CF-LVADs) have significantly improved waitlist mortality, but recent changes to the transplantation listing criteria have dramatically altered the use of MCS for bridge to transplantation. METHODS: Orthotopic heart transplantations from 1988 to 2019 at our institution (Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, MO) were retrospectively reviewed and stratified by pretransplantation MCS status into CF-LVAD (n = 224), pulsatile LVAD (n = 49), temporary MCS (n = 71), and primary transplantation (n = 463) groups. Patients who underwent heart transplantation after the approval of CF-LVAD for bridge to transplantation and before the 2018 allocation policy changes underwent subgroup analysis to evaluate predictors of survival and complications in a contemporary cohort. RESULTS: Rates of primary transplantation declined from 88% to 14% over the course of the study. No significant difference in survival was detected in the cohort stratified by MCS status (P = .18). In the modern era, survival of patients treated with CF-LVADs and temporary MCS was noninferior to that seen with primary transplantation (P = .22). Notable predictors of long-term mortality included lower body mass index, peripheral vascular disease, previous coronary artery bypass graft, ABO nonidentical transplant, and increased donor age (all P ≤ .02). There were no differences in major postoperative complications. CONCLUSIONS: CF-LVAD has grown to account for the majority of transplantations at our center in the last decade, with no adverse effect on survival or postoperative complications. Temporary MCS increased after the 2018 listing criteria change, with acceptable early outcomes.
引用
- Finnan MJ, Bakir NH, Itoh A, et al. 30 Years of Heart Transplant: Outcomes After Mechanical Circulatory Support From a Single Center. Ann Thorac Surg. 2021. PMID: 33675715. doi:10.1016/j.athoracsur.2021.01.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。